- Home
- NEXN vs TSHA Comparison
NEXN vs TSHA Comparison
Compare NEXN & TSHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NEXN
- TSHA
- Stock Information
- Founded
- NEXN 2007
- TSHA 2019
- Country
- NEXN Israel
- TSHA United States
- Employees
- NEXN N/A
- TSHA N/A
- Industry
- NEXN Computer Software: Programming Data Processing
- TSHA Biotechnology: Pharmaceutical Preparations
- Sector
- NEXN Technology
- TSHA Health Care
- Exchange
- NEXN Nasdaq
- TSHA Nasdaq
- Market Cap
- NEXN 669.0M
- TSHA 728.4M
- IPO Year
- NEXN 2021
- TSHA 2020
- Fundamental
- Price
- NEXN $10.17
- TSHA $3.00
- Analyst Decision
- NEXN Strong Buy
- TSHA Strong Buy
- Analyst Count
- NEXN 9
- TSHA 7
- Target Price
- NEXN $13.50
- TSHA $8.71
- AVG Volume (30 Days)
- NEXN 390.9K
- TSHA 2.6M
- Earning Date
- NEXN 08-13-2025
- TSHA 08-12-2025
- Dividend Yield
- NEXN N/A
- TSHA N/A
- EPS Growth
- NEXN N/A
- TSHA N/A
- EPS
- NEXN 0.75
- TSHA N/A
- Revenue
- NEXN $371,746,000.00
- TSHA $8,098,000.00
- Revenue This Year
- NEXN $5.43
- TSHA N/A
- Revenue Next Year
- NEXN N/A
- TSHA N/A
- P/E Ratio
- NEXN $12.78
- TSHA N/A
- Revenue Growth
- NEXN 9.65
- TSHA N/A
- 52 Week Low
- NEXN $6.93
- TSHA $1.05
- 52 Week High
- NEXN $12.60
- TSHA $3.31
- Technical
- Relative Strength Index (RSI)
- NEXN 53.43
- TSHA 63.38
- Support Level
- NEXN $9.07
- TSHA $2.76
- Resistance Level
- NEXN $10.65
- TSHA $3.05
- Average True Range (ATR)
- NEXN 0.52
- TSHA 0.15
- MACD
- NEXN 0.01
- TSHA 0.00
- Stochastic Oscillator
- NEXN 69.84
- TSHA 75.51
About NEXN Nexxen International Ltd. American Depository Shares
Nexxen International Ltd is a globalized and flexible advertising technology platform with deep expertise in data and advanced TV that helps empower advertisers, agencies, digital publishers and broadcasters to achieve desired outcomes, including increased efficiency and returns, across the media supply chain. It is a demand-side platform (DSP), supply-side platform (SSP), ad server, and data management platform (DMP) and also delivers a flexible and unified technology stack with and exclusive data at its core. Company operates in America, APAC, EMEA, regions, with majority revenue from America.
About TSHA Taysha Gene Therapies Inc.
Taysha Gene Therapies Inc is a patient-centric gene therapy company to eradicate monogenic CNS disease. It is focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the CNS in both rare and large patient populations. The company develops and commercializes transformative gene therapy treatments. Its product pipeline includes, TSHA-102 which is a is a self-complementary intrathecally delivered AAV9 gene transfer therapy in clinical evaluation for Rett syndrome.